Sep 29, 2022 7:30am EDT Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
Sep 15, 2022 7:00am EDT Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
Jun 07, 2022 4:05pm EDT Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET
May 17, 2022 8:00am EDT Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the ASGCT 25th Annual Meeting
Jan 27, 2022 7:30am EST Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
Sep 15, 2021 8:00am EDT Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV
Aug 26, 2021 8:00am EDT Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV
Jul 29, 2021 8:00am EDT Excision BioTherapeutics Appoints Industry Veteran Lisa Danzig, M.D., as Chief Medical Officer